Reason for the notification
| |
Initial notification /Amendment
|
Initial notification
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
| |
Name
|
Smith & Nephew plc
|
LEI
|
213800ZTMDN8S67S1H61
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
| |
Description of the financial instrument, type of instrument
|
Smith & Nephew plc Ordinary Shares of USD 0.20 each
|
Identification code
|
ISIN: GB0009223206
|
Nature of the transaction
|
Performance Share Awards granted at target on 21 May 2021 under the Smith & Nephew Global Share Plan 2020.
|
Date of Transaction
|
2021 - 05 - 21
|
Place of Transaction
|
London Stock Exchange (XLON)
|
Name (Position)
|
Director / PDMR
|
Price (£)
|
Volume
|
Aggregated information
|
Bradley Cannon
(President Sports Medicine & ENT)
|
PDMR
|
15.495
|
57,367
|
N/A Single Transaction
|
Peter Coenen
(President EMEA Region)
|
PDMR
|
15.495
|
31,627
|
N/A Single Transaction
|
Phil Cowdy
(Chief Business Development & Corporate Affairs Officer)
|
PDMR
|
15.495
|
25,605
|
N/A Single Transaction
|
Roland Diggelmann
(Chief Executive Officer)
|
Executive
Director
|
15.495
|
96,174
|
N/A Single Transaction
|
Myra Eskes
(President APAC Region)
|
PDMR
|
15.495
|
32,625
|
N/A Single Transaction
|
Simon Fraser
(President Advanced Wound Management)
|
PDMR
|
15.495
|
49,153
|
N/A Single Transaction
|
Melissa Guerdan
(Chief Quality & Regulatory Affairs Officer)
|
PDMR
|
15.495
|
30,423
|
N/A Single Transaction
|
Skip Kiil
(President Orthopaedics)
|
PDMR
|
15.495
|
70,367
|
N/A Single Transaction
|
Elga Lohler
(Chief HR Officer)
|
PDMR
|
15.495
|
32,622
|
N/A Single Transaction
|
Anne-Françoise Nesmes
(Chief Financial Officer)
|
Executive
Director
|
15.495
|
51,468
|
N/A Single Transaction
|
Catheryn O'Rourke
(Chief Legal & Compliance Officer)
|
PDMR
|
15.495
|
34,098
|
N/A Single Transaction
|
Vasant Padmanabhan
(President Research & Development)
|
PDMR
|
15.495
|
31,967
|
N/A Single Transaction
|
Susan Swabey
(Company Secretary)
|
PDMR
|
15.495
|
5,484
|
N/A Single Transaction
|
Award vesting as % of salary at date of grant
| ||
Sector based peer group
|
FTSE100 peer group
| |
Below the index
|
Nil
|
Nil
|
Equaling the index
|
8.6%
|
8.6%
|
8% above the index
|
34.4%
|
34.4%
|
Return on Invested Capital
Year ended 31 December 2023
|
Award vesting as a % of salary
|
Below 9.8%
|
Nil
|
9.8%
|
17.2%
|
11.8%
|
34.4%
|
13.8%
|
68.8%
|
Three years ended 31 December 2023
|
Award vesting as a % of salary
|
Below Threshold
|
Nil
|
Threshold (-8% of target)
|
17.2%
|
Target - set by reference to our expectations
|
34.4%
|
Maximum or above (+8% of target)
|
68.8%
|
Cumulative free cash flow
Three years ended 31 December 2023
|
Award vesting as % of salary
|
Below $1,370m
|
Nil
|
$1,370m
|
17.2%
|
$1,712m
|
34.4%
|
$2,054m
|
68.8%
|
Attachments
- Original document
- Permalink
Disclaimer
Smith & Nephew plc published this content on 21 May 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 21 May 2021 17:18:05 UTC.